Europe. Country/populations

[Uhohinc]

1 Russia[5] 144,031,000 16.91 0.17 250,000 399 146,270,033 January 1, 2015 Official estimate
2 Germany 81,276,000 9.54 0.32 256,000 220 81,083,600 September 30, 2014 Official estimate 81 million population sub-total
3 Turkey 78,214,000 9.18 1.34 1,035,000 52 77,695,904 December 31, 2014 Official estimate
4 United Kingdom 64,915,000 7.62 0.63 406,000 110 64,105,700 July 1, 2013 Official estimate 65 146
5 France 64,304,000 7.55 0.45 289,000 154 66,121,000 April 1, 2015 Monthly official estimate 65 211
6 Italy 60,963,000 7.16 0.49 298,000 141 60,788,845 November 30, 2014 Monthly official estimate 60 271
7 Spain 46,335,000 5.44 -0.28 -129,000 - 46,464,053 July 1, 2014 Official estimate 46 317
8 Ukraine[6] 42,850,000 5.03 -0.32 -136,000 - 42,726,067 March 1, 2015 Monthly official estimate
9 Poland 38,494,000 4.52 0.05 20,000 1,334 38,484,000 December 31, 2014 Official estimate
10 Romania 19,822,000 2.33 -0.41 -81,000 - 19,942,642 January 1, 2014 Official estimate
11 Kazakhstan 17,543,000 2.06 1.45 251,000 48 17,458,500 March 1, 2015 Monthly official estimate
12 Netherlands 16,933,000 1.99 0.37 62,000 189 16,918,400 May 21, 2015 Official population clock 17 334
13 Belgium 11,259,000 1.32 0.52 58,000 134 11,239,846 March 1, 2015 Monthly official estimate 11 345
14 Greece 10,769,000 1.26 -0.11 -12,000 - 10,816,286 May 24, 2011 Final 2011 census result
15 Czech Republic 10,535,000 1.24 -0.06 -6,000 - 10,538,275 December 31, 2014 Official estimate 10 355
16 Portugal 10,311,000 1.21 -0.56 -58,000 - 10,427,301 2013 Official estimate
17 Hungary 9,835,000 1.15 -0.28 -28,000 - 9,849,000 December 31, 2014 Official estimate
18 Sweden 9,794,000 1.15 1.03 100,000 68 9,760,142 February 28, 2015 Monthly official estimate 10 365
19 Azerbaijan 9,651,000 1.13 1.23 117,000 57 9,593,000 January 1, 2015 Official estimate
20 Belarus 9,481,000 1.11 0.00 0 - 9,481,100 April 1, 2015 Official estimate
21 Austria 8,608,000 1.01 0.67 57,000 104 8,579,747 January 1, 2015 Official estimate 9 374
22 Switzerland 8,265,000 0.97 0.87 71,000 80 8,211,700 September 30, 2014 Official estimate 8 382
23 Bulgaria 7,185,000 0.84 -0.57 -41,000 - 7,245,677 December 31, 2013 Official estimate
24 Serbia 7,103,000 0.83 -0.41 -29,000 - 7,146,759 January 1, 2014 Official estimate
25 Denmark 5,673,000 0.67 0.48 27,000 145 5,659,715 January 1, 2015 Official estimate 6 388
26 Finland 5,475,000 0.64 0.11 6,000 632 5,473,465 March 31, 2015 Monthly official estimate 5 393
27 Slovakia 5,426,000 0.64 0.13 7,000 537 5,415,949 September 30, 2014 Official estimate
28 Norway 5,194,000 0.61 1.11 57,000 63 5,165,802 January 1, 2015 Official estimate 5 398
29 Ireland 4,630,000 0.54 0.35 16,000 200 4,609,600 April 2014 Official estimate 4 402
30 Croatia 4,230,000 0.50 -0.31 -13,000 - 4,267,558 July 1, 2012 Official estimate
31 Bosnia and Herzegovina 3,750,000 0.44 -0.64 -24,000 - 3,791,622 October 1, 2013 Preliminary 2013 census result
32 Georgia 3,707,000 0.44 -1.23 -46,000 - 3,729,500 January 1, 2015 Official estimate
33 Moldova 3,564,000 0.42 0.48 17,000 145 3,555,200 January 1, 2015 Official estimate
34 Armenia 3,010,000 0.35 -0.03 -1,000 - 3,010,600 December 31, 2014 Monthly official estimate
35 Lithuania 2,906,000 0.34 -0.85 -25,000 - 2,912,566 April 1, 2015 Monthly official estimate
36 Albania 2,887,000 0.34 -0.41 -12,000 - 2,893,005 January 1, 2015 Official estimate
37 Macedonia 2,071,000 0.24 0.15 3,000 478 2,065,769 December 31, 2013 Official estimate
38 Slovenia 2,065,000 0.24 0.15 3,000 477 2,062,731 October 1, 2014 Official estimate
39 Latvia 1,979,000 0.23 -0.90 -18,000 - 1,983,300 April 1, 2015 Monthly official estimate
40 Kosovo[7] 1,867,000 0.22 1.08 20,000 64 1,815,606 December 31, 2012 Official estimate
41 Estonia 1,315,000 0.15 0.46 6,000 152 1,312,252 January 1, 2015 Official estimate
42 Cyprus 876,000 0.10 0.46 4,000 151 865,900 December 31, 2012 Official estimate
43 Montenegro 620,000 0.07 0.00 0 - 620,029 April 1, 2011 2011 census result
44 Luxembourg 570,000 0.07 2.52 14,000 28 562,958 December 31, 2014 Official estimate 1
45 Malta 425,000 0.05 0.47 2,000 147 417,432 November 20, 2011 2011 census result
46 Iceland 331,000 0.04 1.22 4,000 57 329,100 January 1, 2015 Official estimate with Iceland
47 Jersey (UK) 103,000 0.01 0.98 1,000 71 97,857 March 27, 2011 2011 census result
48 Isle of Man (UK) 89,000 0.01 1.14 1,000 61 84,497 March 27, 2011 2011 census result
49 Andorra 78,000 0.01 1.30 1,000 54 76,949 2014 Official estimate
50 Guernsey (UK) 66,000 0.01 1.54 1,000 45 65,150 March 31, 2014 Official estimate
51 Faroe Islands (Denmark) 49,000 0.01 0.00 0 - 48,693 February 1, 2015 Monthly official estimate
52 Liechtenstein 37,000 0.00 0.00 0 - 37,370 December 31, 2014 Official estimate
53 Monaco 37,000 0.00 0.00 0 - 36,950 December 31, 2013 Official estimate
54 Gibraltar (UK)[8] 34,000 0.00 3.03 1,000 23 30,001 2012 Official estimate
55 San Marino 33,000 0.00 0.00 0 - 32,798 February 28, 2015 Monthly official estimate
56 Åland Islands (Finland) 29,000 0.00 0.00 0 - 28,666 December 31, 2013 Official estimate
57 Svalbard and Jan Mayen (Norway) 3,000 0.00 0.00 0 - 2,575 July 1, 2014 Official estimate
58 Vatican City 800 0.00 0.00 0 - 800 2012 Official estimate 402 million population
Total 851,605,800 100.00 0.33 2,802,000 210

[Uhohinc]

Below here are the country's and the populations which would appear to have economy's which can reimburse Clinuvel. Rates go from 1 in 100,000 (Germany, France, UK ) to 1 in 200,000 (Sweden).
Does anyone know (from Europe ) what keeps a Romanian or Greek from going to Germany and seeking as an EPP patient treatment from a German designated Porphyria center? This would make a tremendous difference ?

2 Germany 81,276,000
4 United Kingdom 65,000,000
5 France 64,304,000
6 Italy 60,963,000
7 Spain 46,335,000
12 Netherlands 16,933,000
13 Belgium 11,259,000
15 Czech Republic 10,535,000
16 Portugal 10,311,000
17 Hungary 9,835,000
18 Sweden 9,794,000
21 Austria 8,608,000
22 Switzerland 8,265,000
25 Denmark 5,673,000
26 Finland 5,475,000
27 Slovakia 5,426,000
28 Norway 5,194,000
29 Ireland 4,630,000

[Uhohinc]

I think the present Clinuvel quarter may show when it ends will show at least $13 million in quarterly revenues in late April 2017.

My guess here is that at March 31, 2017 when the present quarter ends only the below governments will be and having purchased Scenesse. The U.K. Is just a beauracracy that probably uses delay and pricing as an excuse to save money on all approved drugs. Maybe the French but since there is no info, I leave them off.

If we take the ratio of EPP at the rate in Switzerland 8 million population a well documented 48 EPP patients and round it off below we can assume Germany 80 million population has a population ten times bigger so there is another 480 EPP patients.

The Netherlands 16 million population has about twice Swiss 8 million so I give them about 100 EPP patients.

The Austrian 8 million population is respective another 50 patients.
If we combine the populations of Norway, Finland and Denmark we get a total population about 16 million combined and that's another 50 EPP patients.

If we give Belgium and Czech and Sweden another rough about 180 EPP patients for there combined populations.

And the Italians seem to have a lower epidemics and seem always at about 120 EPP patients.

And 8 Americans.

That is 1,040 EPP patients that can potentially want Scenesse each two months this summer. With my assuming not all will want Scenesse, I think with the quarter covering 3 months than some patients will overlap a second Sceness each quarter.

Germany 81,276,000
Italy 60,963,000
Netherlands 16,933,000
Belgium 11,259,000
Czech Republic 10,535,000
Sweden 9,794,000
Austria 8,608,000
Switzerland 8,265,000
Denmark 5,673,000
Finland 5,475,000
Norway 5,194,000

[Uhohinc]

Correction here.......Norway/Finland/ other 16 million population should be another 50 patients for a total of 100 EPP patients.

[Uhohinc]

With today's news of German government aloting about 4 implant per approximation of about 400 German EPP patients at about $75,000 Euro per year reimbursements- that is about a max from Germany only of about $30,000,000 in gross sales per year to Clinuvel.

The rest of Europe that can reimburse should get the present quarter Clinuvel is in might see a order for on the pharmacist's shelves i think an order for 1500 units of sale. Without considering France in equation yet.

I think Lachlan Hay has a still tough task in London trying to get Scenesse approved again, but the Germans just legitimatized the Scenesse drug, the therapeutic value, and the price.

Same for Italy. A big one off the checklist.

[Farma Zutical]

Very great, indeed. But $75.000 a year is the initial price before rebate. I think a price per implant around $15.000 is realistic.

[dan.mur...@gmail.com]

Good news indeed. Hopefully the sp starts to get some traction in the right direction. I'm curious about two countries in particular: Norway, which received application from Clinuvel in June last year, and secondly Spain. Sharelooker on Sharescene posted a document in Spanish that had Scenesse listed for EPP as well as Pemphigus and solar urticaria. For additional indications to be applied for in a country within the European union, can some anecdotal evidence or otherwise be used to secure reimbursement let alone approval for use? I am very wary that this could be the case, but then again why shouldn't it? The regulatory landscape in Europe is onerous as well as labyrinthine, but you never know what can happen from country to country. Just look at the UK, they wound the clock back another year just by reclassifying the category that Scenesse could apply for reimbursement under.

[Uhohinc]

I think strongly that a Spanish low level clerical have merely done a old transposed classification of now non-relavent very out of date data of exploratory therapies no longer active and I would not interpret at all that Clinuvel has an Spanish special therapeutic agenda. Maybe an auto fill matrix common repeat error that would not be the duty or knowledge or concern of whom is charged with the (mis) information.

[Maurice]

On Monday, April 10, 2017 at 4:52:28 PM UTC-4, Farma Zutical wrote:
> Very great, indeed. But $75.000 a year is the initial price before rebate. I think a price per implant around $15.000 is realistic.

According to my notes when Intermune got reimbursement in Germany for Esbriet (September 2011) the mandatory rebate was 16%. I haven't researched to see if the figure has changed or not. Additionally, about a year later they set a price with Umbrella Association of German Sick-Funds (GKV-SV) good for 1 year or until costs to the healthcare system in Germany reach 50 million Euros in any 12-month period, at which time the price would be revisited, as required by the AMNOG law.

[Uhohinc]

Populations

[Uhohinc]

• 28

US Ambassador David Satterfield is treating Turkey like a colony, Ankara’s health minister Fahrettin Koca said, commenting on the escalating row over the skyrocketing debt Turkey owes to American drug companies.

“What the ambassador did is neither correct nor ethical. He is using manipulation at a time when we are holding talks with drug companies. He may be able to do such acts in colonies, but this is not such a country,” Koca told reporters on Friday, while visiting the Black Sea province of Samsun. 

ALSO ON RT.COMTurkey announces live-fire drills in Eastern Mediterranean as Erdogan tells Trump Ankara not to blame for regional instability

Koca was referring to the “extremely unfortunate” comments by the US envoy during a trade conference on Wednesday, when Satterfield warned that American pharmaceutical companies “will consider departing the Turkish market or will reduce exposure to Turkish market,” over the outstanding debt – which ballooned from $230 million last year to some $2.3 billion currently.

Turkish President Recep Tayyip Erdogan and Finance Minister Berat Albayrak assured US Commerce Secretary Wilbur Ross that prompt payments will be arranged when Ross raised the issue in 2019, Sutterfied said. Now, however, Turkey is asking US companies to accept significantly reduced repayments. This is unacceptable to Washington, he said.

Meanwhile, Turkish Foreign Minister Mevlut Cavusoglu lashed out at Speaker of the House Nancy Pelosi (D-California) earlier on Friday, criticizing her “blatant ignorance” and threatening that she will “learn to respect the Turkish people’s will.”

Cavusoglu’s angry tweet came after Pelosi sought to criticize US President Donald Trump as a wannabe dictator, arguing the US is a democracy – unlike North Korea, Turkey, Russia or Saudi Arabia.

“We do know who he admires. He admires [Russian President Vladimir] Putin, he admires Kim Jong Un, he admires Erdogan in Turkey," Pelosi told reporters.

READ MORE

US offered Ankara intelligence on Idlib, FM Cavusoglu claims, says S-400 won’t stop Turkey from getting Patriot missiles

The “colonial” row over medical debt and the Cavusoglu-Pelosi diplomatic flare-up are just the latest in the string of sparks between Ankara and Washington in recent years. The US has threatened Turkey with sanctions and kicked Ankara out of the F-35 stealth fighter consortium after the purchase of Russian S-400 air defense systems in July 2019. 

Another round of sanctions threats came in October, after Turkey sent troops into areas of northern Syria held by the US-backed Kurdish militias. Ankara’s move also soured relations with another NATO ally, France, which has since repeatedly butted heads with Turkey over Libya and oil exploration in the Eastern Mediterranean.

More recently, Washington expressed “disappointment” in July, after Erdogan decided to convert Hagia Sophia into a mosque again. The Orthodox cathedral was built by the Byzantines and turned into a mosque after the Ottoman conquest of Constantinople (now Istanbul), but became a museum under Kemal Ataturk, the founder of the modern Turkish republic.

Think your friends would be interested? Share this story!

On Friday, August 4, 2017 at 1:47:42 AM UTC-7 Uhohinc wrote:

Populations

[Uhohinc]

https://www-impact--hta-eu.translate.goog/country-vignettes?_x_tr_sl=pt&_x_tr_tl=en&_x_tr_hl=en-US&_x_tr_pto=nui,sc